The US Justice Department has ended its probe into Federal Reserve chair Jerome Powell, clearing a major roadblock to the confirmation of his successor, Kevin Warsh.
US Attorney for the District of Columbia Jeannine Pirro said on X on Friday that her office was ending its probe into the Fed’s extensive building renovations because the Fed’s inspector general would scrutinise them instead.
The decision ends an investigation, one of several undertaken by the Justice Department into President Donald Trump’s perceived adversaries, that for months had failed to gain traction as prosecutors struggled to articulate a basis to suspect criminal conduct.
A prosecutor handling the case conceded at a closed-door court hearing in March that the government had not yet found any evidence of a crime, and a judge subsequently quashed subpoenas issued to the Federal Reserve.
Advertisement
The judge, James Boasberg, said prosecutors had produced “essentially zero evidence” to suspect Powell of a crime. Boasberg called prosecutors’ justification for the subpoenas “thin and unsubstantiated”.
More recently, prosecutors made an unannounced visit to a construction site at the Fed’s headquarters but were turned away, drawing a rebuke from a defence lawyer in the case who called the manoeuvre “not appropriate”.
Advertisement
The move could lead to a swift confirmation vote by the Senate for Warsh, a former top Fed official whom Trump, a Republican, nominated in January to replace Powell, whose term as chair ends May 15.

Don't Miss:
-
Iran says peace deal with US ‘never been closer’, as Pakistan says final text agreed on
-
Elon Musk becomes world’s first trillionaire after SpaceX IPO
-
Britain’s David Hockney, a giant of contemporary art, dies aged 88
-
2 infants in Hong Kong confirmed severely infected with Covid-19 just days apart
-
Huawei is considering deploying Ascend AI chips in Latin America, cloud chief says

Thai Princess Kept Alive Artificially For More Than Three Years Dies
Indie Film Causes Consternation Among Overseas Chinese
Lowering doses of cancer drugs could slash global health spending by $30B, new research shows